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Chordomas are tumors derived from cells that are remnants of the notochord, particularly from its proximal and distal extremes,
they are mainly midline and represent approximately 1% of all malignant bone tumors and 0.1 to 0.2% of intracranial neoplasms.
Chordomas involving the sellar region are rare. Herein, we describe a 57-year-old male patient presenting with a history of retro-
orbital headache, progressive loss of vision, and clinical features of hypopituitarism, for over 2 months. During evaluation, the CT
scan revealed a large contrast-enhancing intrasellar tumor with a 3.6-cm largest diameter. The patient underwent transsphenoidal
partial resection of the tumor, and histological examination was consistent with the diagnosis of chondroid chordoma. Although
chordomas are rare, they may be considered to constitute a diﬀerential diagnostic of pituitary adenomas, especially if a calciﬁed
intrasellar tumor with bone erosion is diagnosed.
1.Introduction
Chordomasaremidlineslow-growingtumorsthatarisefrom
proximal and distal extreme remnants of the notochord
and represent 1% of all malignant bone tumors and 0.1 to
0.2% of intracranial neoplasms [1, 2]. Approximately 50%
of them develop in the sacrococcygeal region, 35% in the
spheno-occipital region, and 15% in the vertebrae [3]. They
are locally invasive, may metastasize, and are characterized
b yl o c a lr e c u r r e n c e[ 4–6]. The incidence of endocranial
chordomas presents a male/female ratio of 6:5 [7], and, at
the skull base, the incidence is higher in younger patients
(second to ﬁfth decades of life) [2, 5, 8].
Three established categories of intracranial chordomas
were described based on anatomical location and clinical
features: sellar chordomas associated with chiasm compres-
sion and hypopituitarism; parasellar tumors characterized
by oculomotor nerve palsy, optic tract compression, and
hypopituitarism; tumors involving the clival region and
presenting with bilateral sixth cranial nerve paresis and
brainstem compression [9]. Chordomas involving the sellar
region are rare, especially if they are largely or entirely
intrasellar, and, clinically, they may resemble patients with
pituitary adenoma [6, 10].
Inthispaper,wereportapatientpresentingwithalargely
intrasellar chordoma simulating a nonfunctioning pituitary
adenoma.
2.CaseReport
A57-year-oldmanreportedretro-orbitalheadache,diplopia,
progressive loss of vision (predominantly on the right side),
fatigue, nausea, sexual dysfunction, dry skin, sleepiness, and
constipation over a period of two months. He also had
a history of systemic arterial hypertension and was using
a pacemaker due to chagasic heart disease. In his familial
background, he reported diabetes mellitus, thyroid disease,
a death caused by stroke, and no cases of tumors.
On physical examination, the patient presented pos-
tural hypotension and dry skin, any other alteration was2 ISRN Endocrinology
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Figure 1: (a) and (b) CT shows a large heterogeneously contrast-enhanced intrasellar mass (3.6cm in the largest diameter), with suprasellar
extension, invasion of the sphenoid sinus, and erosion of the sellar ﬂoor.
not observed. Ophthalmological evaluation demonstrated
a right-sided papillary defect, and visual ﬁeld examination
revealed a left temporal hemianopsia and a right/right-side
blindness.
Biochemical evaluation revealed a slightly increased
prolactin level (24.7ng/mL, reference value (RV): 2.5–
17); central hypothyroidism, and hypogonadism (TSH
0.23μIU/mL, RV: 0.4–4.0; free T4 0.51ng/dL, RV: 0.8–1.9;
FSH 1.45mIU/mL, RV: 0.7–11.1; LH 0.23mIU/mL, RV:
0.8–7.6; total testosterone <20ng/dL, RV: 181–758); cortisol
and IGF1 were normal (18ug/dL, RV: 5–25; 237.3ng/mL,
RV: 78–258; resp.); GH 0.62ng/mL (RV: 0.0–5.0); beta-
chorionic gonadotropin (hCG), alpha-fetoprotein (FP), and
carcinoembryonic antigen (CEA) were normal; diabetes
insipidusinvestigationalsowasnormal.Itwasnotpossibleto
realize a dynamic evaluation about the diagnosis of GH deﬁ-
ciency.Thecomputedtomography(CT)scanrevealedalarge
heterogeneous contrast-enhanced intrasellar mass (largest
diameter: 3.6cm), with suprasellar extension, invasion of the
sphenoid sinus, and erosion of the sellar ﬂoor (Figures 1(a)
and 1(b)). Magnetic resonance imaging (MRI) was not per-
formed because of the presence of a pacemaker. Initially, the
lesion was considered to be a nonfunctioning pituitary, and
the patient was submitted to a transsphenoidal surgery. The
tumor was not totally removed because of its tight adhesion
to the pituitary stalk. Microcalciﬁcations in the suprasellar
and sellar portions were detected. Macroscopical ﬁndings
showed multiple tan-to-red fragments. On light microscopic
examination, the tumor was composed typically of a lobular
pattern (Figures 2(d) and 3(b)). The lobes are separated by
a framework of ﬁbrous septa of variable thickness, which
in sections appear as septa that run by the thin-walled
vessels giving aspect of papillary structures (Figure 3(a)).
It histologically showed a solid pattern or cordonal of
anastomosing cell cords, with neoplastic cells embedded in
a myxoid intercellular matrix with chondroid diﬀerentiation
(Figure 2(a)). Tumor cells sometimes adopted a pattern of
ﬁne anastomosing cords or appeared in groups of varying
sizes. Some cells showed epithelioid features with large
and eosinophilic cytoplasm or clear cytoplasm,vacuolated
cells contained a single vacuole that rejects the nuclei,
creating an appearance of signet ring cell morphology,
others show multiple vacuoles deﬁning the physaliphorous
cells. The contents of cytoplasmic vacuoles and intercellular
mucoid substance are PAS positive and diastase resistant.
Moreover, the cytoplasm of the neoplastic cells contains
varying amounts of glycogen, PAS+, which is digested
with diastase (Figures 2(b) and 2(c)). Physaliphorous cells
contain multiple vacuoles surrounding the nucleus located
in the center of the cell. The cellularity of the tumor was
variable from ﬁeld to ﬁeld. Mitoses were very rare and
atypical mitoses were not seen. Immunohistochemically, the
neoplastic cells of chordoma were positive for cytokeratin
AE1/AE3 (Figure 2(d)). They were characteristically positive
chordoma cells for EMA (Figure 3(a)) and the protein S-100
(Figure 3(b)) and VIMENTIN (Figure 3(c)). The prolifera-
tion index was low as evidenced by weak nuclear positivity
for Ki67 (Figure 3(d)).
The patient received adequate hormone replacement
before and following surgery. The postoperative evaluation
showedhyponatremiaassociatedtosyndromeofinappropri-
ate secretion of antidiuretic hormone (SIADH). The serum
sodium normalized after ﬂuid restriction. Four months later,
the patient evolved with intense headache and signiﬁcant
worsening of the left-side vision. A frontal craniotomy was
performed for total removal of the tumor. However, an
aneurism of the anterior circulation was ruptured during the
surgery. Therefore, the aneurism was clipped, but the tumor
could not be removed. He stayed 19 days in the intensiveISRN Endocrinology 3
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Figure 2: (a) Photomicrograph demonstrating the typical chordoma cells with large, pleomorphic nuclei and vacuolated cytoplasm
(hematoxylin and eosin stain) forming sheets or lobular structures that are embedded in a mucoid stroma. Characteristic of chordomas
chondroids are the formation of lobules of neoplastic tissue separated by ﬁbrous stroma and areas of chondroid tissue (∗), and vacuolated
cell and lymphocytic inﬁltration. The tumor displays remarkable morphological variation, mainly based on the amount of interstitial matrix
and vacuolated cells; these physaliphorous cells (arrow) with multivacuolated cytoplasm and sometimes pleomorphic nuclei are surrounded
by mucinous extracellular matrix, some with chondroid aspect. Physaliphorous comes from the Greek word physalis (bubble). (b) PAS stain:
the cytoplasm of many tumor cells is strongly PAS positive (arrows), highlighting them against mucoid matrix. The vacuoles, however, are
usually negative. To deﬁne the nature of PAS positive material (glycogen), the technique was repeated in cuts, one of which was previously
handled by diastase. (c) Neoplastic physaliphorous cells with arrows. (d) AE1/AE3: antibodies against keratins clearly show the ratio of
neoplastic cells (dark brown) and interstitial tissue (in blue). The lobules of tumor tissue stand out, surrounded by strands of ﬁbrous tissue.
care unit to receive pneumonia treatment, and he died two
months later.
3. Discussion
We report the case of a patient presenting with a chondroid
chordoma that had an aggressive clinical course.
Chordomasinvolvingthesellarregionareextremelyrare.
According to a recent review, only 22 patients have been
described as possessing primarily intrasellar chordoma since
1960 and 43% of the patients were primarily diagnosed with
a pituitary adenoma [3, 6, 9–21]. This rate of misdiagnosis
mightoccurmainlybecauseintrasellarchordomasmimicthe
clinical and imaging presentations of pituitary adenomas, as
described in the present case and their higher frequency in
relation to the chordomas [22].
The skull base chordomas tend to present osseous
permeation, and have a high rate of recurrence [5, 6]. Their
metastatic potential cannot be estimated by histological
examination, except in cases of sarcomatous transformation
[8, 23].
The only known prognostic study published in 1993
estimated overall survival rates of 51% and 35% at 10 and
20 years, respectively [24].
The imaging method of choice for the pituitary gland
is MRI, but coronal CT with contrast and thin slices may
be obtained in patients who have contraindications to MRI.
On unenhanced CT scan pituitary adenomas are isodense
to adjacent brain parenchyma and show intense contrast
enhancement after injection of contrast material. Bony
erosions are well demonstrated in bone window images. A
sellar chordoma CT scan may reveal a contrast-enhancing
intrasellar mass with bony erosions and calciﬁcations [25].
The immunohistologic proﬁle of chordoma cells is reac-
tivity to cytokeratins, vimentin, and epithelial membrane
antigen (EMA) [26–33]. Approximately 50% of chordomas4 ISRN Endocrinology
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Figure 3: (a) EMA: epithelial membrane antigen positive cells of chordoma in papillary structure. Cytoplasmic pattern with enhanced
cell membrane (insert). (b) S-100: strong nuclear and cytoplasmic positivity. (c) VIM. Cytoplasmic positivity. (d) KI67: positivity in a few
scattered nuclei of neoplastic cells (less than 5%, low proliferation).
are reactive to S-100-protein [27]. Carcinoembryonic anti-
gen in diﬀerential diagnosis has also been reported [30, 32–
34]. Electron microscopy has contributed to the characteri-
zation of chordomas [27].
Transsphenoidalsurgery(gross-totalresection),followed
by radiotherapy, has been the accepted treatment for sellar
chordomas [5, 17, 35]. Unfortunately, in this patient, a
radical excision was not possible because of adherence of the
tumor to the pituitary stalk.
Although sellar chordomas are rare, they should be
included in the diﬀerential diagnosis of tumors in the sellar
region especially if a calciﬁed tumor with bone erosion is
revealed.
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